Wondering if Medpace Holdings is still worth buying after its huge run, or if the smart move now is to wait for a better entry point? You are not alone, and that is exactly what we are going to unpack here.
The stock has pulled back about 6.1% over the last month after a strong year to date jump of 69.1%, and a hefty 63.0% gain over the past year. Zooming out further, Medpace is up 175.1% over three years and 279.5% over five, which naturally raises the question of how much upside is left.
Recent headlines around Medpace continue to highlight its role as a key clinical research partner for biotech and pharma companies, reinforcing the narrative that it is a picks and shovels play on drug development. That backdrop helps explain why…
